A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin

Journal of Clinical Pharmacology

Volumn 48, Issue 9, 2008, Pages 1092-1098

  Rao, N ^a   Dvorchik, B ^b   Sussman, N ^a   Wang, H ^a   Yamamoto, K ^c   Mori, A ^c   Uchimura, T ^c   Chaikin, P ^a  

^a Kyowa Pharmaceutical Inc   (United States)

^b Barry Dvorchik and Associates Inc   (United States)

^c KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Atorvastatin; Drug interaction; Istradefylline; Pharmacokinetics

Indexed keywords

2 HYDROXYATORVASTATIN; 4 HYDROXYATORVASTATIN; ATORVASTATIN; DRUG METABOLITE; GLYCOPROTEIN P; ISTRADEFYLLINE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; HUMAN EXPERIMENT; INSOMNIA; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANTIPARKINSON AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; P-GLYCOPROTEIN; PURINES; PYRROLES;

EID: 49649084692     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008320924     Document Type: Article

References (11)

1. Kieburtz K. Issues in neuroprotection clinical trials in Parkinson's disease. Neurology. 2006 ; 66 (10 suppl 4). S50 - S57.
2. Pinna A., Volpini R., Cristalli G., Morelli M. New adenosine A2A receptor antagonists: actions on Parkinson's disease models. Eur J Pharmacol. 2005 ; 512: 157-164.
3. Bara-Jimenez W., Sherzai A., Dimitrova T., et al. Adenosine A2A receptor antagonist treatment of Parkinson's disease. Neurology. 2003 ; 61: 293-296.
4. Stacy M., and the 6002-US-005/6002-US-006 Clinical Investigator Group. Istradefylline (KW-6002) as adjunctive therapy in patients with advanced Parkinson's disease: a positive safety profile with supporting efficacy. Poster presented at: Movement Disorder Society's 8th International Congress of Parkinson's Disease and Movement Disorders ; June 13-17, 2004 ; Rome, Italy.
5. Hauser RA, Hubble JP, Truong DD, and the Istradefylline US-001 Study Group. Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD. Neurology. 2003 ; 61: 297-303.
6. Jacobsen W., Kuhn B., Soldner A., et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000 ; 28: 1369-1378.
7. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003 ; 42: 1141-1160.
8. Siedlik PH, Olson SC, Yang B. -B, Stern RH Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol. 1999 ; 39: 501-504.
9. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V., Lettieri J., Sundaresen P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther. 2000 ; 68: 391-400.
10. Kantola T., Kivisto KT, Neuvonen PJ Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther. 1998 ; 64: 58-65.
11. Lilja JJ, Kivisto KT, Neuvonen PJ Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther. 1999 ; 66: 118-127.